Matthias Waldert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthias Waldert has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Tobias Klatte
Medical University of Vienna
7 shared publicationsMesut Remzi
Department of Urology, Medical University of Vienna, Vienna, Austria
6 shared publicationsMichael Marberger
Department of Urology, Medical University of Vienna, Vienna, Austria
4 shared publicationsGeorg Schatzl
Medical University of Vienna
3 shared publicationsAndrea Haitel
2 shared publicationsHans Christoph Klingler
Department of Urology, Medical University of Vienna, Vienna, Austria
2 shared publications
Latest Publications
- 24 September 2013
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 125 (21) , 669-673
Transperineal template-guided biopsy for diagnosis of prostate cancer in patients with at least two prior negative biopsies
To evaluate the prostate cancer (PCa) detection rate, PCa location, PCa significance and complications of a standardized 24-core template-guided transperineal biopsy (TPB) approach in patients with at least two negative transrectal biopsies.
- 24 September 2013
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 125 (21) , 669-673
Transperineal template-guided biopsy for diagnosis of prostate cancer in patients with at least two prior negative biopsies
To evaluate the prostate cancer (PCa) detection rate, PCa location, PCa significance and complications of a standardized 24-core template-guided transperineal biopsy (TPB) approach in patients with at least two negative transrectal biopsies.
- 1 June 2011
- Published by SAGE Publications in Journal of Endourology
- Vol. 25 (6) , 969-973
Floseal Reduces the Incidence of Lymphoceles After Lymphadenectomies in Laparoscopic and Robot-Assisted Extraperitoneal Radical Prostatectomy
Purpose: To evaluate the efficacy and cost-effectiveness of FloSeal® hemostatic matrix in preventing lymphocele development after pelvic lymphadenectomy (PLA). Materials and Methods: This was a single-center, matched comparison of lymphadenectomies in laparoscopic and robot-assisted extraperitoneal radical prostatectomy (ERP) performed with and without FloSeal between January 2008 and October 2009. FloSeal was applied topically in the lymphadenectomy zone immediately after node resection. Cost analysis for lymphocele treatment was performed. Results: A total of 142 patients underwent PLA with ERP (32 with FloSeal, 110 without FloSeal). The mean number of lymph nodes removed was 6.5±4.5 (range 2–20). Median prostate-specific antigen concentration was 8.5 ng/mL (range 1.5–24 ng/mL). There was one (3.1%) symptomatic lymphocele in the FloSeal group compared with 16 (14.5%) in the non-FloSeal group. The median number of lymph nodes removed was 8 (range 5–20) in the FloSeal group and seven (range 3–25) in the non-FloSeal group. The only lymphocele in the FloSeal group was treated with percutaneous drainage alone. In the non-FloSeal group, six symptomatic lymphoceles were managed conservatively—four with percutaneous puncture and six with fenestration after percutaneous drainage. The mean cost per patient of treating symptomatic lymphoceles was €327 ($455) in the FloSeal group (total costs €10,481 [$14,559]) vs €553 ($769) (total costs €60,870 [$84,551]) in the non-FloSeal group. Conclusions: These preliminary data suggest that the use of FloSeal after lymphadenectomy can reduce the number of symptomatic lymphoceles and is cost-effective.
- 1 June 2011
- Published by SAGE Publications in Journal of Endourology
- Vol. 25 (6) , 969-973
Floseal Reduces the Incidence of Lymphoceles After Lymphadenectomies in Laparoscopic and Robot-Assisted Extraperitoneal Radical Prostatectomy
Purpose: To evaluate the efficacy and cost-effectiveness of FloSeal® hemostatic matrix in preventing lymphocele development after pelvic lymphadenectomy (PLA). Materials and Methods: This was a single-center, matched comparison of lymphadenectomies in laparoscopic and robot-assisted extraperitoneal radical prostatectomy (ERP) performed with and without FloSeal between January 2008 and October 2009. FloSeal was applied topically in the lymphadenectomy zone immediately after node resection. Cost analysis for lymphocele treatment was performed. Results: A total of 142 patients underwent PLA with ERP (32 with FloSeal, 110 without FloSeal). The mean number of lymph nodes removed was 6.5±4.5 (range 2–20). Median prostate-specific antigen concentration was 8.5 ng/mL (range 1.5–24 ng/mL). There was one (3.1%) symptomatic lymphocele in the FloSeal group compared with 16 (14.5%) in the non-FloSeal group. The median number of lymph nodes removed was 8 (range 5–20) in the FloSeal group and seven (range 3–25) in the non-FloSeal group. The only lymphocele in the FloSeal group was treated with percutaneous drainage alone. In the non-FloSeal group, six symptomatic lymphoceles were managed conservatively—four with percutaneous puncture and six with fenestration after percutaneous drainage. The mean cost per patient of treating symptomatic lymphoceles was €327 ($455) in the FloSeal group (total costs €10,481 [$14,559]) vs €553 ($769) (total costs €60,870 [$84,551]) in the non-FloSeal group. Conclusions: These preliminary data suggest that the use of FloSeal after lymphadenectomy can reduce the number of symptomatic lymphoceles and is cost-effective.
- 11 May 2011
- Published by Springer Nature in World Journal of Urology
- Vol. 30 (2) , 233-237
Is 153Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?
To evaluate the impact of biphosphonate administration on subsequent 153Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) uptake in bone metastases of patients with castration-resistant prostate cancer.
- 11 May 2011
- Published by Springer Nature in World Journal of Urology
- Vol. 30 (2) , 233-237
Is 153Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?
To evaluate the impact of biphosphonate administration on subsequent 153Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) uptake in bone metastases of patients with castration-resistant prostate cancer.
- 7 July 2010
- Published by Springer Nature in World Journal of Urology
- Vol. 28 (4) , 531-535
External validation of the preoperative anatomical classification for prediction of complications related to nephron-sparing surgery
Ficarra et al. (Eur Urol 56:786–793, 2009) published a preoperative anatomical classification (PADUA) to assess the impact of anatomical parameters of renal tumors on complication rate of nephron-sparing surgery (NSS). The objective of this study is to provide a bi-center external validation of this classification using the technique of hilar arterial clamping during open and laparoscopic NSS and to correlate the PADUA score to the ischemia time.
- 7 July 2010
- Published by Springer Nature in World Journal of Urology
- Vol. 28 (4) , 531-535
External validation of the preoperative anatomical classification for prediction of complications related to nephron-sparing surgery
Ficarra et al. (Eur Urol 56:786–793, 2009) published a preoperative anatomical classification (PADUA) to assess the impact of anatomical parameters of renal tumors on complication rate of nephron-sparing surgery (NSS). The objective of this study is to provide a bi-center external validation of this classification using the technique of hilar arterial clamping during open and laparoscopic NSS and to correlate the PADUA score to the ischemia time.
- 1 April 2010
- Published by Elsevier in European Urology
- Vol. 57 (4) , 661-666
Hybrid Renal Cell Carcinomas Containing Histopathologic Features of Chromophobe Renal Cell Carcinomas and Oncocytomas Have Excellent Oncologic Outcomes
- 1 April 2010
- Published by Elsevier in European Urology
- Vol. 57 (4) , 661-666
Hybrid Renal Cell Carcinomas Containing Histopathologic Features of Chromophobe Renal Cell Carcinomas and Oncocytomas Have Excellent Oncologic Outcomes
- Open Access
- 12 December 2008
- Published by Wiley in BJU International
- Vol. 103 (1) , 66-70
The oncological results of laparoscopic nephroureterectomy for upper urinary tract transitional cell cancer are equal to those of open nephroureterectomy
OBJECTIVE: To compare the overall, tumour‐specific, recurrence‐free, and progression‐ free survival of patients with upper urinary tract transitional cell carcinoma (UUT‐TCC) treated with laparoscopic nephroureterectomy (LNU) or standard open NU (ONU). PATIENTS AND METHODS: Clinical, pathological and follow‐up data were analysed for 43 LNUs and 59 ONUs performed at our institution from 1999 to 2006. In LNU the kidney was removed laparoscopically as in radical nephrectomy, but without transecting the ureter. The specimen was then removed intact with the entire ureter and a bladder cuff through a nonmuscle‐splitting supra‐inguinal incision. ONU was performed through separate intercostal and supra‐inguinal incisions with the entire specimen being removed intact with a bladder cuff through the latter. RESULTS: The mean ( sd ) follow‐up was 41 (20) months for LNU and 41 (29) for ONU. Pathological staging was: pTa 26% vs 20%, pT1 21% vs 27%, pT2 12% vs 17%, pT3 42% vs 34% for LNU and ONU, respectively. In all, seven vs six patients had positive nodes on final histology. Recurrent tumours in the bladder were detected in 26% of patients after LNU and in 27% after ONU after the mean follow‐up. There were no local recurrences after LNU but there was local recurrence in six patients after ONU. There were no port‐site metastases during the follow‐up. Five LNU patients and seven ONU patients developed distant or lymph node metastasis. The actuarial 5‐year tumour free‐survival rate was 79% in the LNU group vs 76% in the ONU group ( P = 0.82). The actuarial disease‐specific survival at 5‐years was 85% for LNU and 80% for ONU patients ( P = 0.62). The surgical approach did not influence recurrence or survival. CONCLUSION: Oncological results of LNU and ONU are comparable. The lower morbidity of LNU offers advantages for the patient.
- 12 December 2008
- Published by Wiley in BJU International
- Vol. 103 (1) , 66-70
Open AccessThe oncological results of laparoscopic nephroureterectomy for upper urinary tract transitional cell cancer are equal to those of open nephroureterectomy
OBJECTIVE: To compare the overall, tumour‐specific, recurrence‐free, and progression‐ free survival of patients with upper urinary tract transitional cell carcinoma (UUT‐TCC) treated with laparoscopic nephroureterectomy (LNU) or standard open NU (ONU). PATIENTS AND METHODS: Clinical, pathological and follow‐up data were analysed for 43 LNUs and 59 ONUs performed at our institution from 1999 to 2006. In LNU the kidney was removed laparoscopically as in radical nephrectomy, but without transecting the ureter. The specimen was then removed intact with the entire ureter and a bladder cuff through a nonmuscle‐splitting supra‐inguinal incision. ONU was performed through separate intercostal and supra‐inguinal incisions with the entire specimen being removed intact with a bladder cuff through the latter. RESULTS: The mean ( sd ) follow‐up was 41 (20) months for LNU and 41 (29) for ONU. Pathological staging was: pTa 26% vs 20%, pT1 21% vs 27%, pT2 12% vs 17%, pT3 42% vs 34% for LNU and ONU, respectively. In all, seven vs six patients had positive nodes on final histology. Recurrent tumours in the bladder were detected in 26% of patients after LNU and in 27% after ONU after the mean follow‐up. There were no local recurrences after LNU but there was local recurrence in six patients after ONU. There were no port‐site metastases during the follow‐up. Five LNU patients and seven ONU patients developed distant or lymph node metastasis. The actuarial 5‐year tumour free‐survival rate was 79% in the LNU group vs 76% in the ONU group ( P = 0.82). The actuarial disease‐specific survival at 5‐years was 85% for LNU and 80% for ONU patients ( P = 0.62). The surgical approach did not influence recurrence or survival. CONCLUSION: Oncological results of LNU and ONU are comparable. The lower morbidity of LNU offers advantages for the patient.